Vera Therapeutics stock (US92337F1075): FDA alignment on earlier ORIGIN 3 analysis puts IgAN program in focus

Vera Therapeutics shares on Nasdaq in the United States traded higher after the company announced alignment with the U.S. FDA on an earlier eGFR analysis in the pivotal ORIGIN 3 study for IgA nephropathy, setting up key efficacy data for the third quarter of 2026 and a potential sBLA filing in the fourth quarter.

Vera Therapeutics shares on Nasdaq in the United States drew investor attention after the company reported on 06/02/2026 that it has reached alignment with the U.S. Food and Drug Administration (FDA) on a revised and earlier analysis plan for the estimated glomerular filtration rate (eGFR) endpoint in the ORIGIN 3 Phase 3 study in adults with IgA nephropathy (IgAN), with top-line eGFR results now targeted for the third quarter of 2026 and a potential supplemental Biologics License Application (sBLA) for full approval of atacicept planned for the fourth quarter of 2026, according to a company press release.

According to Vera Therapeutics, the updated analysis plan was agreed in discussions with the FDA and is designed to support a potential transition from accelerated to full approval for atacicept in IgAN, with the company highlighting that it retains global development and commercial rights to the asset and that the eGFR-based assessment is expected to be conducted on an earlier dataset than previously planned, as outlined in its 06/02/2026 news release and related SEC filing.

The stock traded at USD 46.30 on 06/03/2026 on Nasdaq under the ticker VERA, according to Nasdaq price data as of that date, reflecting the U.S.-based primary listing and providing the home-country hook for investors following the biotech sector in the United States.

In Germany, Vera Therapeutics is also available to retail investors via venues such as Tradegate, where the shares changed hands at around EUR 42.60 on 06/03/2026, giving investors in the eurozone an additional access point alongside the U.S. home market.

As of: 03.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: VERA
• Sector/industry: Biotechnology, immunology-focused
• Headquarters/country: Brisbane, California, United States
• Core markets: United States and other major pharmaceutical markets
• Key revenue drivers: Development and potential commercialization of atacicept and other immunology candidates
• Home exchange/listing venue: Nasdaq (VERA)
• Trading currency: USD

Vera Therapeutics: core business model

Vera Therapeutics focuses on advancing late-stage biologic therapies for serious immunological and kidney disorders, with future revenue expected to be driven primarily by successful regulatory approvals and commercialization of its lead candidates such as atacicept.

Vera Therapeutics in peer comparison

In the context of U.S.-listed biotechnology peers targeting kidney and immune-mediated diseases, Vera Therapeutics is often compared with companies such as Travere Therapeutics and Calliditas Therapeutics, both of which also work on therapies for IgA nephropathy or related renal conditions. Travere Therapeutics, for example, has been developing sparsentan for IgAN and focal segmental glomerulosclerosis, and its recent regulatory and commercial milestones in these indications provide a reference point for how payers and regulators may view novel kidney disease therapies. Calliditas Therapeutics, meanwhile, markets budesonide-based therapy Tarpeyo in IgAN in the United States, offering a precedent for pricing, uptake and regulatory pathways in this niche, and giving investors a framework to gauge how an additional biologic such as atacicept could fit into the treatment landscape if full approval is granted.

Conclusion

The newly announced alignment with the U.S. FDA on an earlier eGFR analysis in the ORIGIN 3 study places regulatory timing for atacicept at the center of the Vera Therapeutics equity story, with top-line data expected in the third quarter of 2026 and a potential sBLA in the fourth quarter of 2026. In peer context, the presence of other IgA nephropathy and renal disease players such as Travere Therapeutics and Calliditas Therapeutics illustrates both the competitive landscape and the growing recognition of kidney disease as a key focus area in biotechnology, highlighting how Vera Therapeutics is positioning itself within this evolving market. For investors, the coming data and regulatory milestones will likely remain the main driver of sentiment on the stock, alongside broader sector risk appetite and funding conditions for late-stage biotechnology names.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.